PHARMARON Aktie

 

Morgan Stanley released a research report estimating that, for Chinese CROs and CDMOs, which contributed more than half of their revenues to the US market last year, the impact from potential tariff policies will be less than 10%, which is basically controllable. The broker was more concerned about whether financing activities a......

TheraCryf PLC on Monday said it has signed a master service agreement with Pharmaron UK Ltd to progress development of its Orexin-1 addiction programme.The Macclesfield,......

300 Beagles Per Week!? US Continues To Fund Dog Experiments in China Authored by Jeremy Portnoy via RealClearInvestigations, Topline: A Chinese lab is continuing to receive funds from the U.S. to conduct cruel studies on beagles, according to contracts obtained by the nonprofit White Coat Waste Project and shared with the New York Post. Key facts: The $124,200 contract was awarded by the National Institutes of Health's National Center for Advancing Translational Sciences using money from the Pentagon, for the experiments on beagle puppies — as well as mice and rats — at the Beijing-based company's lab from September 2023 until May 2025. The Chinese company Pharmaron uses the funds to test pharmaceuticals for neurological disorders on 300 beagles per week, as well as mice and rats, White Coat Waste found. Some of the dogs are as young as eight months. Those that suffer organ dysfunction are euthanized, the contract states. Pharmaron's proposal to the NIH promises to comply with the Anima...

BOCI released a research report expecting China's healthcare sector to be re-rated in 2025, mainly due to the government's continued support for innovation and favorable policies for medical and commercial insurance, increasing risk appetite for China's healthcare on lower interest rates in the US, improved cost cont......

Pharmaron's HK stock jumps most in 4-1/2 months on solid earnings estimates...

Das Instrument 17Q1 CNE100003PG4 PHARMARON BEIJING H YC1 EQUITY wird ex Dividende/Zinsen gehandelt am 27.06.2024 The instrument 17Q1 CNE100003PG4 PHARMARON BEIJING H YC1 EQUITY has its ex-dividend/interest day on 27.06.2024...